Current challenges for using the Kansas City Cardiomyopathy Questionnaire to obtain a standardized patient-reported health status outcome.
作者信息
Stogios Nicolette, Fezza Gabriel, Wong Julia V, Ross Heather J, Farkouh Michael E, Nolan Robert P
机构信息
Behavioural Cardiology Research Unit, University Health Network (UHN), Toronto, ON, Canada.
Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
出版信息
Eur J Heart Fail. 2021 Feb;23(2):205-207. doi: 10.1002/ejhf.2139. Epub 2021 Mar 8.
Abstract
摘要
相似文献
1
Current challenges for using the Kansas City Cardiomyopathy Questionnaire to obtain a standardized patient-reported health status outcome.
Eur J Heart Fail. 2021 Feb;23(2):205-207. doi: 10.1002/ejhf.2139. Epub 2021 Mar 8.
2
Comparison of the Kansas City Cardiomyopathy Questionnaire and Minnesota Living With Heart Failure Questionnaire in Predicting Heart Failure Outcomes.
Am J Cardiol. 2019 Mar 1;123(5):807-812. doi: 10.1016/j.amjcard.2018.11.037. Epub 2018 Dec 4.
3
Interaction between the Kansas City Cardiomyopathy Questionnaire and the Pocock's clinical score in predicting heart failure outcomes.
Qual Life Res. 2016 May;25(5):1245-55. doi: 10.1007/s11136-015-1154-9. Epub 2015 Oct 11.
4
Patterns of Change in Individual Domains of the Kansas City Cardiomyopathy Questionnaire With a Palliative Care Intervention for Patients With Advanced Heart Failure: Insights from PAL-HF.
J Card Fail. 2021 Dec;27(12):1476-1478. doi: 10.1016/j.cardfail.2021.02.007. Epub 2021 Feb 26.
5
Patient-Reported Outcomes in Patients with Cardiomyopathy.
Curr Cardiol Rep. 2021 Jun 14;23(7):91. doi: 10.1007/s11886-021-01511-5.
6
Psychometric properties of the Japanese version of the Kansas City Cardiomyopathy Questionnaire in Japanese patients with chronic heart failure.
Health Qual Life Outcomes. 2020 Jul 17;18(1):236. doi: 10.1186/s12955-020-01483-0.
7
Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review.
J Am Coll Cardiol. 2020 Nov 17;76(20):2379-2390. doi: 10.1016/j.jacc.2020.09.542.
8
Kansas City Cardiomyopathy Questionnaire Score Is Associated With Incident Heart Failure Hospitalization in Patients With Chronic Kidney Disease Without Previously Diagnosed Heart Failure: Chronic Renal Insufficiency Cohort Study.
Circ Heart Fail. 2015 Jul;8(4):702-8. doi: 10.1161/CIRCHEARTFAILURE.115.002097. Epub 2015 May 18.
9
Kansas City Cardiomyopathy Quality Score Indicates Sustained Health Status Improvement in Patients After TMVr.
J Am Coll Cardiol. 2020 May 5;75(17):2107-2109. doi: 10.1016/j.jacc.2020.03.034.
10
The utility of a specific measure for heart transplant patients: reliability and validity of the Kansas City Cardiomyopathy Questionnaire.
Transplantation. 2008 Sep 27;86(6):804-10. doi: 10.1097/TP.0b013e318183eda4.
引用本文的文献
1
Evaluating the Prognostic Value of Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores for 6-Month Readmissions in Southeast Asian Populations With Heart Failure.
Clin Cardiol. 2025 Jul;48(7):e70136. doi: 10.1002/clc.70136.
2
Sodium Glucose Cotransporter Inhibition in Acute Heart Failure: An In-Depth Review.
CJC Open. 2024 Dec 27;7(4):380-389. doi: 10.1016/j.cjco.2024.12.008. eCollection 2025 Apr.
3
The Relationship Between the Kansas City Cardiomyopathy Questionnaire and Electrocardiographic Parameters in Predicting Outcomes After Cardiac Resynchronization Therapy.
Life (Basel). 2024 Nov 28;14(12):1564. doi: 10.3390/life14121564.
4
New York Heart Association Class and Kansas City Cardiomyopathy Questionnaire in Acute Heart Failure.
JAMA Netw Open. 2023 Oct 2;6(10):e2339458. doi: 10.1001/jamanetworkopen.2023.39458.
本文引用的文献
1
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
N Engl J Med. 2021 Jan 14;384(2):105-116. doi: 10.1056/NEJMoa2025797. Epub 2020 Nov 13.
2
Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review.
J Am Coll Cardiol. 2020 Nov 17;76(20):2379-2390. doi: 10.1016/j.jacc.2020.09.542.
3
Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction.
Eur J Heart Fail. 2020 Jun;22(6):999-1005. doi: 10.1002/ejhf.1810. Epub 2020 Apr 2.
4
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Circulation. 2020 Jan 14;141(2):90-99. doi: 10.1161/CIRCULATIONAHA.119.044138. Epub 2019 Nov 17.
5
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
JACC Heart Fail. 2019 Oct;7(10):862-874. doi: 10.1016/j.jchf.2019.05.015. Epub 2019 Jul 10.
6
Does heart failure-specific health status identify patients with bothersome symptoms, depression, anxiety, and/or poorer spiritual well-being?
Eur Heart J Qual Care Clin Outcomes. 2019 Jul 1;5(3):233-241. doi: 10.1093/ehjqcco/qcy061.
7
Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION.
Eur J Heart Fail. 2019 Jan;21(1):63-70. doi: 10.1002/ejhf.1299. Epub 2018 Aug 31.
8
Health-Related Quality of Life Outcomes in PARADIGM-HF.
Circ Heart Fail. 2017 Aug;10(8). doi: 10.1161/CIRCHEARTFAILURE.116.003430.
9
Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire.
Circ Cardiovasc Qual Outcomes. 2015 Sep;8(5):469-76. doi: 10.1161/CIRCOUTCOMES.115.001958.
10
Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments.
Circulation. 2007 Apr 17;115(15):1975-81. doi: 10.1161/CIRCULATIONAHA.106.670901. Epub 2007 Apr 9.
Zotero 插件